Tekla Capital Management LLC Atreca, Inc. Transaction History

Tekla Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.87 - $6.29 $658,297 - $1.44 Million	-229,372 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$4.91 - $9.07 $604,185 - $1.12 Million	-123,052 Reduced 34.92%	229,372 $1.43 Million
Q1 2020 May 14, 2020	SELL	$11.4 - $27.28 $1.97 Million - $4.71 Million	-172,472 Reduced 32.86%	352,424 $5.83 Million
Q4 2019 Feb 13, 2020	BUY	$9.68 - $18.67 $3.46 Million - $6.68 Million	357,651 Added 213.85%	524,896 $8.12 Million
Q3 2019 Nov 13, 2019	SELL	$10.42 - $22.04 $80,807 - $170,920	-7,755 Reduced 4.43%	167,245 $2.05 Million
Q2 2019 Aug 14, 2019	BUY	$17.07 - $18.84 $2.99 Million - $3.3 Million	175,000 New	175,000 $3.3 Million

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.